

## News Release

February 12, 2016  
Carna Biosciences, Inc.  
Kohichiro Yoshino, President & CEO  
(Code:4572, Jasdaq Glowth)  
<http://www.carnabio.com/english/>

### **Carna Biosciences Announces Opening of San Francisco Research Center**

Carna Biosciences, a biopharmaceutical company focused on the discovery and development of proprietary kinase inhibitor drugs to treat serious unmet medical needs, today announced that CarnaBio USA, Inc. a Carna's 100% wholly-owned subsidiary, has opened a new research center, "CarnaBio C-Lab", in South San Francisco. The new facility is located at Johnson & Johnson Innovation, JLABS (JLABS) @ South San Francisco (JLABS @ SSF). The C-Lab will be focused primarily on development of novel technologies enabling the efficient research to address undruggable/difficult drug targets. In addition, the facility will be a key addition to CarnaBio's global research network of academia and biotechs in the US to facilitate effective collaborations.

"We are very excited to announce the opening of CarnaBio C-Lab at JLABS @ SSF," said Kohichiro Yoshino, PhD, Founder, President and CEO of Carna Biosciences. "Many big pharma and biotech firms are in the San Francisco Bay Area, and it is the best place to expand our footprint in the US," Dr. Yoshino, continued. "Our drug discovery research has been successfully progressed under the leadership of Dr. Masaaki Sawa, and now it's time to take it to the next level. This innovation center will be crucial for the future success."

The C-Lab will be directed by Masaaki Sawa, Ph.D., Chief Scientific Officer, and a member of the Board of Directors at Carna Biosciences.

"In addition to facilitating to access to the cutting-edge information in the US, the new research center will accelerate new collaborations with top scientists in the US, enhancing our research and development of innovative drugs," said Dr. Masaaki Sawa.

"We are excited to be part of the JLABS @ SSF community. The C-Lab will enable us to develop innovative products to add more value to our partners," said Akiko Futamura, PhD, President and CEO of CarnaBio USA.

#### **About CarnaBio C-Lab**

Date of establishment: February 12, 2016

Address: JLABS @ South San Francisco (JLABS @ SSF), 329 Oyster Point Boulevard, South San Francisco, CA 94080, USA

Head of C-Lab: Masaaki Sawa, Ph.D.

Areas of research: development of novel technologies targeting undruggable/difficult drug targets